Korean J Cerebrovasc Surg.
2006 Dec;8(4):273-278.
Recombinant Factor VIIa Treatment for Acute Intracerebral Hemorrhage
- Affiliations
-
- 1Department of Neurosurgery, Cerebrovascular Center, Yongdong Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. jyahn@yumc.yonsei.ac.kr
Abstract
- Intracerebral hemorrhage is a lethal stroke type with a high morbidity and mortality. Hematoma growth is one of the independent determinants of neurological and functional outcomes after intracerebral hemorrhage. Attenuation of growth is an important therapeutic strategy. Hemostatic therapeutic intervention, given ultra-early in the course of intracerebral hemorrhage, may thus improve clinical outcomes by arresting ongoing bleeding and limiting in turn the size of the hematoma. Recombinant factor VIIa is a hemostatic drug approved to treat bleeding in hemophilia or other coagulopathy; it has also been reported to arrest bleeding in nonhemophilic cases. We reviewed of the published articles specifically addressing clinical trials of recombinant factor VIIa treatment for acute intracerebral hemorrhage and evaluate the safety and feasibility of it.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- The prophylactic use of recombinant factor VIIa in a patient with DeBakey type III aortic dissection: A case report
- Diffuse alveolar hemorrhage and recombinant factor VIIa treatment in pediatric patients
- A Case of Successful Treatment of Childhood Intractable Gastrointestinal Hemorrhage with Low Dose Recombinant Activated Factor VII (NovoSeven (R))
- Post-operative Bleeding due to Acquired Hemophilia Successfully Treated with Recombinant Factor VIIa: Case Report
- Orthognathic Surgery in a Patient with Factor VII Deficiency
